TickerTalks
Browse all tickers →
TickerTalks›$KLRA
KLKLRA

Kailera Therapeutics, Inc.

$KLRA·$2.7B·Biotechnology·Healthcare
$19.97-3.4%1Y-20.5%
Mentions · last 7 days
2026-07-03: 0 posts2026-07-04: 0 posts2026-07-05: 0 posts2026-07-06: 2 posts2026-07-07: 28 posts2026-07-08: 5 posts2026-07-09: 3 posts39
Price updated 6m ago·X counts updated 4d ago
KLKLRA
$KLRAKailera Therapeutics, Inc.
$19.97-3.43%39 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $KLRA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-07-13

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Kailera Therapeutics at $2.7B market cap — the pre-revenue GLP-1 biotech loading for the August print.

Kailera Therapeutics is a clinical-stage biotech focused on next-generation GLP-1 obesity drugs. This is a recent listing with a $2.7B market cap and no meaningful revenue — the equity is priced entirely on the probability of Kailera's GLP-1 candidate reaching commercial scale.

Where the setup is:

  • The business is entirely pre-commercial: Q1 revenue was $0 against a $2.68B market cap — the equity is a probabilistic bet on the GLP-1 pipeline reaching Phase 3 and either commercializing or being acquired by big pharma.
  • The new executive appointment is a meaningful signal: Kathleen Tregoning's A-Award of 175,000 shares valued at $4.08M ($23/share equivalent) as she was appointed to Kailera — that's the kind of high-value executive compensation package that companies use to attract senior talent for scaling; it's typically done in preparation for milestones.
  • The tape reflects post-IPO patience: 4% below the 50-day moving average, no 52-week range data (recent IPO) — that pattern is normal for a recently-listed biotech waiting for the first substantive earnings print; volume at 58% of 30-day confirms the marginal buyer is still evaluating.

August 25 earnings will be the first substantive commentary on the GLP-1 pipeline progress; any dated Phase 2 readout or strategic-partnership disclosure is what would resolve the coil upward. Absent specific pipeline milestones, the tape stays speculative on the GLP-1 category tailwind. Position sizing dominates any trade — this is pure event-driven biotech at scale.

What to watch: August 25 earnings — first substantive GLP-1 pipeline update, cash-runway commentary, and any strategic-partnership disclosure. A pipeline slippage or a widened cash-burn is what would flip the coil into cooling.

On the calendar: 2026-08-25 — Q2 earnings

float missing

Read the AI verdict + X sentiment for $KLRA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $KLRA.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $KLRA

Partial — These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders; exposure exists but is diluted by diverse end markets and revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+13.2%YTD
+43.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-16.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-24.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
41.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 26, 2026$-3650.00$-0.78-470867.7%
Q1 2026May 26, 2026$-0.67$-0.78+13.5%
Next earningsTue, Aug 25·consensus EPS $-0.80

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.67$-68.3M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$3.61-$4.26 – -$2.940
FY27$0$0 – $0-$3.84-$4.53 – -$2.800
FY28$0$0 – $0-$3.54-$5.51 – -$2.090
FY29$138.9M$138.9M – $138.9M-$4.01-$4.01 – -$4.015
FY30$522.1M$522.1M – $522.1M-$2.80-$2.80 – -$2.803

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-4.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β0.005-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyApr 20Investments, Lp Rtw10% owner500.0K sh$8.0MBuyApr 20Andrew T. KaplanDirector8.4M sh$134.4MBuyApr 20Bain Capital Investors Llc10% owner8.4M sh$134.4MBuyApr 20Adam KoppelDirector1.6M sh$25.0MBuyApr 20Bain Capital Life Sciences Investors, Llc10% owner1.6M sh$25.0M
+ 21 other (14 awards · 6 conversions · 1 exempt) in window

See when $KLRA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJul 83
AI summary

Initial Form 3 ownership statement filed by Kathleen Tregoning, a newly reportable officer or director at Kailera Therapeutics, Inc., disclosing initial beneficial ownership of company securities upon becoming a Section 16 reporting person. Routine Section 16(a) disclosure triggered by appointment or election to a qualifying role. No operational implications for the company.

SC 13DActivist position (5%+)Apr 23SC 13D
SC 13DActivist position (5%+)Apr 23SC 13D
8-KCharter amendmentApr 208-K — Item 5.03: Charter amendment · Item 8.01: Other event
424B4Prospectus supplement (offering)Apr 17424B4
3New insider — initial holdingsApr 163
3New insider — initial holdingsApr 163
3New insider — initial holdingsApr 163
+ 27 other (17 3s · 1 10-Q · 1 earnings 8-K · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Winseekingalpha.com·5d agoWhy Is Kailera Therapeutics Stock Falling Tuesday?benzinga.com·6d agoKailera's GLP-1 drug meets main goal of late-stage trialsreuters.com·7d agoKailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officerglobenewswire.com·15d agoBiotech ETF Index Surges 10% After Rebalanceetftrends.com·18d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$AURA$MRNA$SLS$IBRX$REGN$ALLO$CRNX
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport